Abingdon Health is pleased to announce it has been awarded a grant by Innovate UK to develop a dual capability colorimetric and time-resolved fluorescence reader.
Abingdon’s Innovate UK grant funded innovation will build on Abingdon’s existing ADxLR5® lateral flow reader to develop a dual capability reader which will allow for multiplexing of colorimetric and fluorescence labels in a single test, maximising the individual benefits of each label for particular analytes. The reader will incorporate the use of time-resolved fluorescence (TRFL) technology to overcome background auto-fluorescence which can limit assay sensitivity in classical fluorescence.
Fiona Smith, Sales and Marketing Director of Abingdon Health, commented:
“It is fantastic news for the company to win this Innovate UK grant, and adds to previous grant success earlier this year with our Mastitis diagnostic project. The ability to combine both colorimetric and time-resolved fluorescence into a single reader unit will provide a greater choice of assay label to our contract customers without the need for compromise.
“We will draw on our previous experience with our CE marked, and FDA registered, ADxLR5® reader to ensure this dual capability reader meets this unmet market need, and meets the standards required to deliver an accurate and reliable flexible testing system.”
For companies interested in talking to Abingdon Health about our lateral flow contract services or reader technology please contact a member of our team on +44 (0) 1904 406082 or at firstname.lastname@example.org.
About Abingdon Health
Abingdon Health is a UK-based developer and manufacturer of lateral flow immunoassay tests and readers.
Abingdon Health offers development and manufacturing services for customers looking to develop new assays or looking to transfer existing laboratory-based assays to a lateral flow format. Abingdon Health takes projects from initial concept through to routine and large-scale manufacturing. Abingdon’s patented lateral flow reader, the ADxLR5®, is CE marked and FDA registered and can be fully customised to meet the needs of clients looking for a quantitative solution for a lateral flow assay. Abingdon Health is focused on developing lateral flow assays in partnership with key opinion leaders that meet significant unmet needs.